- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B
Hye Yeon Chon 1 2 , Jae Seung Lee 1 3 2 , Hye Won Lee 1 3 2 , Ho Soo Chun 1 2 , Beom Kyung Kim 1 3 2 , Jun Yong Park 1 3 2 , Do Young Kim 1 3 2 , Sang Hoon Ahn 1 3 2 , Seung Up Kim 1 3 2
Affiliations
Affiliations
1
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
2
Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea.
3
Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.
PMID: 33242365 DOI: 10.1111/hepr.13600
Abstract
Aim: Risk prediction models for hepatocellular carcinoma (HCC) development are available. However, the influence of antiviral therapy (AVT) on these models in patients with chronic hepatitis B (CHB) is unknown.
Methods: The dynamic changes in risk prediction models during AVT and the association between risk prediction model and the risk of CHB-related HCC development were investigated. Between 2005 and 2017, 4,917 patients with CHB (3,361 non-cirrhotic, 1,556 cirrhotic) were recruited.
Results: The mean age of the study population was 49.3 years and 60.6% (n=2,980) of the patients were male. The mean Chinese University-HCC (CU-HCC) score was 12.7 at baseline in the overall study population, and decreased significantly (mean, 8.7) after 1 year of AVT (p<0.001). The score was maintained throughout 5 years of AVT (mean, 8.4-8.8; p>0.05). The proportion of high-risk patients (CU-HCC score ≥ 20) was 28.9% at baseline, and decreased significantly after 1 year of AVT (5.0%; p<0.001), and remained stable through 5 years of AVT (2.2-3.6%; p>0.05). In addition to the score at baseline, the CU-HCC score at 1 year of AVT independently predicted the risk of HCC development (hazard ratio=1.072; p<0.001), together with male gender and platelet count (all p<0.05).
Conclusions: The CU-HCC score significantly decreased at 1 year of AVT and was maintained thereafter. The CU-HCC score after 1 year of AVT independently predicted the risk of HCC development in patients with CHB.
Keywords: Antiviral therapy; Chronic hepatitis B; Hepatocellular carcinoma; Risk prediction model.
This article is protected by copyright. All rights reserved. |
|